SCHEMBL1603697

SCHEMBL1603697

CCCCCCCCCCCCCCCCCCOCC(=O)O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.69
EPHX2 P34913 1/20 0.58
PAM P19021 2/20 0.53
PLA2G4B P0C869 2/20 0.51
GPR84 Q9NQS5 7/20 0.50
PPARG P37231 6/20 0.50
PPARD Q03181 6/20 0.50
PPARA Q07869 6/20 0.50
HDAC11 Q96DB2 5/20 0.50
TSHR P16473 4/20 0.50
ALDH1A1 P00352 2/20 0.50
TLR2 O60603 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
MEN1 O00255 2/20 0.50
FABP4 P15090 2/20 0.50
PTPN1 P18031 2/20 0.50
KMT2A Q03164 2/20 0.50
SLC22A6 Q4U2R8 1/20 0.50
SLC22A8 Q8TCC7 1/20 0.50
ESR1 P03372 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4651569 1.00 CES2 (0.69) CES2EPHX2PAMPLA2G4BGPR84
SCHEMBL7249862 1.00 CES2 (0.69) CES2EPHX2PAMPLA2G4BGPR84
SCHEMBL8198788 1.00 CES2 (0.69) CES2EPHX2PAMPLA2G4BGPR84
SCHEMBL501889 1.00 CES2 (0.69) CES2EPHX2PAMPLA2G4BGPR84
SCHEMBL21611691 1.00 CES2 (0.69) CES2EPHX2PAMPLA2G4BGPR84
SCHEMBL7763197 1.00 CES2 (0.69) CES2EPHX2PAMPLA2G4BGPR84
SCHEMBL3296171 1.00 CES2 (0.69) CES2EPHX2PAMPLA2G4BGPR84
SCHEMBL8626082 1.00 CES2 (0.69) CES2EPHX2PAMPLA2G4BGPR84
SCHEMBL21611665 1.00 CES2 (0.69) CES2EPHX2PAMPLA2G4BGPR84
SCHEMBL7611940 1.00 CES2 (0.69) CES2EPHX2PAMPLA2G4BGPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113827738-B Sialic acid modified dexamethasone palmitate liposome and preparation and application thereof 沈阳药科大学 2024-04-09 CN claimed
CN-113827738-B Sialic acid modified dexamethasone palmitate liposome and preparation and application thereof 沈阳药科大学 2024-04-09 CN disclosed
CN-113827738-B Sialic acid modified dexamethasone palmitate liposome and preparation and application thereof 沈阳药科大学 2024-04-09 CN disclosed
CN-113827738-A Sialic acid modified dexamethasone palmitate liposome and preparation and application thereof 沈阳药科大学 2021-12-24 CN disclosed
US-9663444-B2 Heteroatom containing substituted fatty acids COMPLEXA, INC. (US) 2017-05-30 US disclosed
US-20170113999-A9 HETEROATOM CONTAINING SUBSTITUTED FATTY ACIDS COMPLEXA, INC. (US) 2017-04-27 US disclosed
US-20140256814-A1 HETEROATOM CONTAINING SUBSTITUTED FATTY ACIDS COMPLEXA, INC. (US) 2014-09-11 US disclosed
EP-2483233-A2 HETEROATOM CONTAINING SUBSTITUTED FATTY ACIDS Miller, Raymond A. (US) 2012-08-08 EP disclosed
WO-2011041639-A2 HETEROATOM CONTAINING SUBSTITUTED FATTY ACIDS MILLER RAYMOND A (US) 2011-04-07 WO disclosed
US-20110082206-A1 HETEROATOM CONTAINING SUBSTITUTED FATTY ACIDS COMPLEXA, INC. 2011-04-07 US disclosed
EP-1970409-A1 Compositions for articles comprising replicated microstructures GENERAL ELECTRIC COMPANY (US) 2008-09-17 EP disclosed
EP-1828319-A1 COMPOSITIONS FOR ARTICLES COMPRISING REPLICATED MICROSTRUCTURES General Electric Company (US) 2007-09-05 EP disclosed
US-20070082988-A1 Compositions for articles comprising replicated microstructures GENERAL ELECTRIC COMPANY (US) 2007-04-12 US disclosed
WO-2006065542-A1 COMPOSITIONS FOR ARTICLES COMPRISING REPLICATED MICROSTRUCTURES GENERAL ELECTRIC COMPANY (US) 2006-06-22 WO disclosed
US-20060128853-A1 Compositions for articles comprising replicated microstructures GENERAL ELECTRIC COMPANY (US) 2006-06-15 US disclosed
EP-0262399-B1 CYCLIC ENOL DERIVATIVES, PRODUCTION AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 1993-02-03 EP disclosed
US-4925868-A CARDIOVASCULAR DISORDERS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1990-05-15 US disclosed
EP-0262399-A2 Cyclic enol derivatives, production and use thereof Takeda Chemical Industries, Ltd. (JP) 1988-04-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170113999-A9 HETEROATOM CONTAINING SUBSTITUTED FATTY ACIDS FFAR2, FFAR1, FFAR4 CES2 547/4885EPHX2 279/4885PAM 637/4885
US-20140256814-A1 HETEROATOM CONTAINING SUBSTITUTED FATTY ACIDS FFAR2, FFAR1, FFAR4 CES2 547/4885EPHX2 279/4885PAM 637/4885
US-20110082206-A1 HETEROATOM CONTAINING SUBSTITUTED FATTY ACIDS FFAR2, FFAR1, FFAR4 CES2 547/4885EPHX2 279/4885PAM 637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.